ITGB1 (also known as CD29) and CD44 are reported as tumor stem cell markers, and the presence of tumor stem cells could affect the drug treatment and subsequent tumor recurrence (Tomasetti et al. 2017). This evidence concerns the gene CD44 and neoplasm.